First Header Logo Second Header Logo

Boris C. Pasche MD, PhD

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentCancer Biology
Address
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionWake Forest School of Medicine
    DepartmentInternal Medicine, Hematology & Oncology


    Collapse Research 
    Collapse research activities and funding
    P30CA012197     (PASCHE, BORIS)Mar 1, 1976 - Jan 31, 2022
    NIH
    Cancer Center Support Grant
    Role: Principal Investigator
    K08CA076156     (PASCHE, BORIS)Jul 1, 1999 - Jun 30, 2002
    NIH
    TYPE 1 TGF BETA RECEPTOR ALTERATIONS
    Role: Principal Investigator
    R21CA082516     (PASCHE, BORIS)Sep 1, 2001 - Aug 31, 2004
    NIH
    Mutations of the type 1 TGF beta receptor in cancer
    Role: Principal Investigator
    R01CA112520     (PASCHE, BORIS)Dec 1, 2004 - Jul 31, 2014
    NIH
    TGF-beta polymorphisms and breast cancer in families
    Role: Principal Investigator
    R01CA108741     (PASCHE, BORIS)Feb 24, 2006 - Jan 31, 2010
    NIH
    TGF-beta pathway polymorphisms and colon cancer risk
    Role: Principal Investigator
    R01CA137000     (PASCHE, BORIS)Jan 1, 2010 - Dec 31, 2015
    NIH
    TGFBR1 Signaling in Colorectal Cancer
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hughes RT, McTyre ER, LeCompte M, Cramer CK, Munley MT, Laxton AW, Tatter SB, Ruiz J, Pasche B, Watabe K, Chan MD. Clinical Outcomes of Upfront Stereotactic Radiosurgery Alone for Patients With 5 to 15 Brain Metastases. Neurosurgery. 2019 08 01; 85(2):257-263. PMID: 29982831.
      Citations:    
    2. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 08; 20(8):1070-1082. PMID: 31262657.
      Citations:    
    3. Jimenez H, Wang M, Zimmerman JW, Pennison MJ, Sharma S, Surratt T, Xu ZX, Brezovich I, Absher D, Myers RM, DeYoung B, Caudell DL, Chen D, Lo HW, Lin HK, Godwin DW, Olivier M, Ghanekar A, Chen K, Miller LD, Gong Y, Capstick M, D'Agostino RB, Munden R, Merle P, Barbault A, Blackstock AW, Bonkovsky HL, Yang GY, Jin G, Liu L, Zhang W, Watabe K, Blackman CF, Pasche BC. Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2?T-type voltage-gated calcium channels and Ca2+ influx. EBioMedicine. 2019 Jun; 44:209-224. PMID: 31160272.
      Citations:    
    4. Sharma S, Wu SY, Jimenez H, Xing F, Zhu D, Liu Y, Wu K, Tyagi A, Zhao D, Lo HW, Metheny-Barlow L, Sun P, Bourland JD, Chan MD, Thomas A, Barbault A, D'Agostino RB, Whitlow CT, Kirchner V, Blackman C, Pasche B, Watabe K. Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF. EBioMedicine. 2019 Jun; 44:194-208. PMID: 31129098.
      Citations:    
    5. Song Q, Hawkins GA, Wudel L, Chou PC, Forbes E, Pullikuth AK, Liu L, Jin G, Craddock L, Topaloglu U, Kucera G, O'Neill S, Levine EA, Sun P, Watabe K, Lu Y, Alexander-Miller MA, Pasche B, Miller LD, Zhang W. Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq. Cancer Med. 2019 06; 8(6):3072-3085. PMID: 31033233.
      Citations:    
    6. Dohm A, Su J, McTyre ER, Taylor JM, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow LJ, O'Neill S, Bellinger C, Dotson T, Pasche B, Watabe K, Chan MD, Ruiz J. Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. Int J Biol Markers. 2019 Mar; 34(1):90-97. PMID: 30854931.
      Citations:    
    7. Enomoto LM, Fenstermaker J, Desnoyers RJ, Pasche BC, Blackstock AW, Howerton RM, Clark CJ, Levine EA, Shen P. Oncology Navigation Decreases Time to Treatment in Patients with Pancreatic Malignancy. Ann Surg Oncol. 2019 May; 26(5):1512-1518. PMID: 30652224.
      Citations:    
    8. Guan M, Cho S, Petro R, Zhang W, Pasche B, Topaloglu U. Natural language processing and recurrent network models for identifying genomic mutation-associated cancer treatment change from patient progress notes. JAMIA Open. 2019 Apr; 2(1):139-149. PMID: 30944913.
      Citations:    
    9. Li X, Zhang S, Zhang Q, Wei X, Pan Y, Zhao J, Xin X, Qin C, Wang X, Li J, Yang F, Zhao Y, Yang M, Wang Q, Zheng Z, Zheng X, Yang X, Whitlow CT, Gurcan MN, Zhang L, Wang X, Pasche BC, Gao M, Zhang W, Chen K. Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study. Lancet Oncol. 2019 02; 20(2):193-201. PMID: 30583848.
      Citations:    
    10. Li X, Pasche B, Zhang W, Chen K. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. JAMA Oncol. 2018 12 01; 4(12):1691-1698. PMID: 30098163.
      Citations:    
    11. Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D'Agostino RB, Watabe K. Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Cancer Res. 2018 08 01; 78(15):4316-4330. PMID: 30026327.
      Citations:    
    12. Liu L, Ruiz J, O'Neill SS, Grant SC, Petty WJ, Yang M, Chen K, Topaloglu U, Pasche B, Zhang W. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer. 2018 04 12; 17(1):81. PMID: 29650000.
      Citations:    
    13. Rimkus TK, Carpenter RL, Sirkisoon S, Zhu D, Pasche BC, Chan MD, Lesser GJ, Tatter SB, Watabe K, Debinski W, Lo HW. Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res. 2018 05 15; 78(10):2589-2600. PMID: 29463580.
      Citations:    
    14. Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, Watabe K, Lo HW, Thomas A, Godwin D, Blackstock W, Mudry A, Posey J, O'Connor R, Brezovich I, Bonin K, Kim-Shapiro D, Barbault A, Pasche B. Use of non-ionizing electromagnetic fields for the treatment of cancer. Front Biosci (Landmark Ed). 2018 Jan 01; 23:284-297. PMID: 28930547.
      Citations:    
    15. Shenker RF, Hughes RT, McTyre ER, Lanier C, Lo HW, Metheny-Barlow L, Su J, Thomas A, Brown DR, Avery T, Pasche B, Cramer CK, Laxton AW, Tatter SB, Watabe K, Chan MD. Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. J Radiosurg SBRT. 2018; 5(4):277-283. PMID: 30538888.
      Citations:    
    16. Jin G, Xu C, Zhang X, Long J, Rezaeian AH, Liu C, Furth ME, Kridel S, Pasche B, Bian XW, Lin HK. Atad3a suppresses Pink1-dependent mitophagy to maintain homeostasis of hematopoietic progenitor cells. Nat Immunol. 2018 Jan; 19(1):29-40. PMID: 29242539.
      Citations:    
    17. Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC, Petty WJ, Alistar AT, Levine EA, Staren ED, Langefeld CD, Miller V, Singal G, Petro RM, Robinson M, Blackstock W, Powell BL, Wagner LI, Foley KL, Abraham E, Pasche B, Zhang W. Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. Theranostics. 2017; 7(11):2914-2923. PMID: 28824725.
      Citations:    
    18. Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, Lo HW. Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget. 2017 Sep 26; 8(43):73947-73963. PMID: 29088759.
      Citations:    
    19. Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017 06; 18(6):770-778. PMID: 28495639.
      Citations:    
    20. Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED, D'Agostino RB, Petro RM, Blackstock W, Powell BL, Abraham E, Pasche B, Zhang W. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol. 2017 05 04; 10(1):100. PMID: 28472989.
      Citations:    
    21. Principe DR, DeCant B, Staudacher J, Vitello D, Mangan RJ, Wayne EA, Mascariñas E, Diaz AM, Bauer J, McKinney RD, Khazaie K, Pasche B, Dawson DW, Munshi HG, Grippo PJ, Jung B. Loss of TGFß signaling promotes colon cancer progression and tumor-associated inflammation. Oncotarget. 2017 Jan 17; 8(3):3826-3839. PMID: 27270652.
      Citations:    
    22. Pasche B, Pennison MJ, DeYoung B. Lynch Syndrome Testing: A Missed Opportunity in the Era of Precision Medicine. JAMA. 2016 Jul 05; 316(1):38-9. PMID: 27380341.
      Citations:    
    23. Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo HW, Carpenter RL, Metheny-Barlow LJ, Zhou X, Qasem SA, Pasche B, Watabe K. Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer. Cancer Res. 2016 09 01; 76(17):4970-80. PMID: 27364556.
      Citations:    
    24. Capstick M, Gong Y, Pasche B, Kuster N. An HF exposure system for mice with improved efficiency. Bioelectromagnetics. 2016 May; 37(4):223-33. PMID: 27037618.
      Citations:    
    25. Principe DR, DeCant B, Mascariñas E, Wayne EA, Diaz AM, Akagi N, Hwang R, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ. TGFß Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. Cancer Res. 2016 05 01; 76(9):2525-39. PMID: 26980767.
      Citations:    
    26. Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw. 2014 Sep; 12(9):1326-38. PMID: 25190698.
      Citations:    
    27. Pasche B, Grant SC. Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. JAMA. 2014 May 21; 311(19):1975-6. PMID: 24846033.
      Citations:    
    28. Pasche B, Wang M, Pennison M, Jimenez H. Prevention and treatment of cancer with aspirin: where do we stand? Semin Oncol. 2014 Jun; 41(3):397-401. PMID: 25023355.
      Citations:    
    29. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C, Grippo PJ. TGF-ß: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014 Feb; 106(2):djt369. PMID: 24511106.
      Citations:    
    30. Pasche B, Pennison MJ, Jimenez H, Wang M. TGFBR1 and cancer susceptibility. Trans Am Clin Climatol Assoc. 2014; 125:300-12. PMID: 25125747.
      Citations:    
    31. Zimmerman JW, Jimenez H, Pennison MJ, Brezovich I, Morgan D, Mudry A, Costa FP, Barbault A, Pasche B. Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies. Chin J Cancer. 2013 Nov; 32(11):573-81. PMID: 24206915.
      Citations:    
    32. Liu NN, Xi Y, Callaghan MU, Fribley A, Moore-Smith L, Zimmerman JW, Pasche B, Zeng Q, Li YL. SMAD4 is a potential prognostic marker in human breast carcinomas. Tumour Biol. 2014 Jan; 35(1):641-50. PMID: 23975369.
      Citations:    
    33. Pasche B. Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA. 2013 Jun 26; 309(24):2598-9. PMID: 23800937.
      Citations:    
    34. Pasche B. Aspirin--from prevention to targeted therapy. N Engl J Med. 2012 Oct 25; 367(17):1650-1. PMID: 23094728.
      Citations:    
    35. Chen J, Liu RY, Yang L, Zhao J, Zhao X, Lu D, Yi N, Han B, Chen XF, Zhang K, He J, Lei Z, Zhou Y, Pasche B, Li X, Zhang HT. A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol. 2013 Feb; 139(2):231-42. PMID: 23052692.
      Citations:    
    36. Borate U, Absher D, Erba HP, Pasche B. Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML. Expert Rev Anticancer Ther. 2012 Oct; 12(10):1289-97. PMID: 23176617.
      Citations:    
    37. Liu RY, Song X, Chen P, Lei Z, Miao J, Yi N, Zhang K, Pasche B, Zhang HT. Association between IL6 -174G/C and cancer: A meta-analysis of 105,482 individuals. Exp Ther Med. 2012 Apr; 3(4):655-664. PMID: 22969947.
      Citations:    
    38. Tuupanen S, Yan J, Turunen M, Gylfe AE, Kaasinen E, Li L, Eng C, Culver DA, Kalady MF, Pennison MJ, Pasche B, Manne U, de la Chapelle A, Hampel H, Henderson BE, Marchand LL, Hautaniemi S, Askhtorab H, Smoot D, Sandler RS, Keku T, Kupfer SS, Ellis NA, Haiman CA, Taipale J, Aaltonen LA. Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583. Cancer Genet. 2012 Jan-Feb; 205(1-2):25-33. PMID: 22429595.
      Citations:    
    39. Pasche B, Absher D. Whole-genome sequencing: a step closer to personalized medicine. JAMA. 2011 Apr 20; 305(15):1596-7. PMID: 21505140.
      Citations:    
    40. Kaklamani V, Yi N, Sadim M, Siziopikou K, Zhang K, Xu Y, Tofilon S, Agarwal S, Pasche B, Mantzoros C. The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. BMC Med Genet. 2011 Apr 13; 12:52. PMID: 21489227.
      Citations:    
    41. Moore-Smith L, Pasche B. TGFBR1 signaling and breast cancer. J Mammary Gland Biol Neoplasia. 2011 Jun; 16(2):89-95. PMID: 21461994.
      Citations:    
    42. Kaklamani V, Yi N, Zhang K, Sadim M, Offit K, Oddoux C, Ostrer H, Mantzoros C, Pasche B. Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism. 2011 Sep; 60(9):1234-43. PMID: 21397927.
      Citations:    
    43. Yi N, Kaklamani VG, Pasche B. Bayesian analysis of genetic interactions in case-control studies, with application to adiponectin genes and colorectal cancer risk. Ann Hum Genet. 2011 Jan; 75(1):90-104. PMID: 20846215.
      Citations:    
    44. Pasche B, Wisinski KB, Sadim M, Kaklamani V, Pennison MJ, Zeng Q, Bellam N, Zimmerman J, Yi N, Zhang K, Baron J, Stram DO, Hayes MG. Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs. J Exp Clin Cancer Res. 2010 May 25; 29:57. PMID: 20500843.
      Citations:    
    45. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010 May; 8(5):562-94. PMID: 20495085.
      Citations:    
    46. Pasche B, Yi N. Candidate gene association studies: successes and failures. Curr Opin Genet Dev. 2010 Jun; 20(3):257-61. PMID: 20417090.
      Citations:    
    47. Pasche B. The cover. Physichromie no. 965. JAMA. 2010 Mar 17; 303(11):1015. PMID: 20233811.
      Citations:    
    48. Pasche B, McNutt RA, Fontanarosa PB. Caring for patients with cancer. JAMA. 2010 Mar 17; 303(11):1094-5. PMID: 20233832.
      Citations:    
    49. Bellam N, Pasche B. Tgf-beta signaling alterations and colon cancer. Cancer Treat Res. 2010; 155:85-103. PMID: 20517689.
      Citations:    
    50. Pasche B. Cancer genetics. Introduction. Cancer Treat Res. 2010; 155:xi-xii. PMID: 20698080.
      Citations:    
    51. Adrian K, Strouch MJ, Zeng Q, Barron MR, Cheon EC, Honasoge A, Xu Y, Phukan S, Sadim M, Bentrem DJ, Pasche B, Grippo PJ. Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer. Cancer Res. 2009 Dec 15; 69(24):9169-74. PMID: 19951995.
      Citations:    
    52. Lei Z, Liu RY, Zhao J, Liu Z, Jiang X, You W, Chen XF, Liu X, Zhang K, Pasche B, Zhang HT. TGFBR1 haplotypes and risk of non-small-cell lung cancer. Cancer Res. 2009 Sep 01; 69(17):7046-52. PMID: 19690145.
      Citations:    
    53. Pasche B, Myers RM. One step forward toward identification of the genetic signature of glioblastomas. JAMA. 2009 Jul 15; 302(3):325-6. PMID: 19602695.
      Citations:    
    54. Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, Kuster N, Pasche B. Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res. 2009 Apr 14; 28:51. PMID: 19366446.
      Citations:    
    55. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009 Apr; 5(4):200-6. PMID: 19337284.
      Citations:    
    56. Zeng Q, Phukan S, Xu Y, Sadim M, Rosman DS, Pennison M, Liao J, Yang GY, Huang CC, Valle L, Di Cristofano A, de la Chapelle A, Pasche B. Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. Cancer Res. 2009 Jan 15; 69(2):678-86. PMID: 19147584.
      Citations:    
    57. Varga J, Pasche B. Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr Opin Rheumatol. 2008 Nov; 20(6):720-8. PMID: 18946334.
      Citations:    
    58. Kaklamani VG, Sadim M, Koumantaki Y, Kaklamanis P, Pasche B. Role of polymorphisms in Adamantiades-Behçet's disease. J Rheumatol. 2008 Dec; 35(12):2376-8. PMID: 18925687.
      Citations:    
    59. Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, Baron JA, Ahsan H, Mantzoros C, Pasche B. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA. 2008 Oct 01; 300(13):1523-31. PMID: 18827209.
      Citations:    
    60. Valle L, Serena-Acedo T, Liyanarachchi S, Hampel H, Comeras I, Li Z, Zeng Q, Zhang HT, Pennison MJ, Sadim M, Pasche B, Tanner SM, de la Chapelle A. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science. 2008 Sep 05; 321(5894):1361-5. PMID: 18703712.
      Citations:    
    61. Pasche B. Familial colorectal cancer: a genetics treasure trove for medical discovery. JAMA. 2008 Jun 04; 299(21):2564-5. PMID: 18523226.
      Citations:    
    62. Rebbeck TR, Antoniou AC, Llopis TC, Nevanlinna H, Aittomäki K, Simard J, Spurdle AB, Couch FJ, Pereira LH, Greene MH, Andrulis IL, Pasche B, Kaklamani V, Hamann U, Szabo C, Peock S, Cook M, Harrington PA, Donaldson A, Male AM, Gardiner CA, Gregory H, Side LE, Robinson AC, Emmerson L, Ellis I, Peyrat JP, Fournier J, Vennin P, Adenis C, Muller D, Fricker JP, Longy M, Sinilnikova OM, Stoppa-Lyonnet D, Schmutzler RK, Versmold B, Engel C, Meindl A, Kast K, Schaefer D, Froster UG, Chenevix-Trench G, Easton DF. No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Res Treat. 2009 May; 115(1):185-92. PMID: 18523885.
      Citations:    
    63. Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, Ahsan H, Pasche B, Mantzoros C. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res. 2008 May 01; 68(9):3178-84. PMID: 18451143.
      Citations:    
    64. Fontanarosa PB, Pasche B, DeAngelis CD. Genetics and genomics for clinicians. JAMA. 2008 Mar 19; 299(11):1364-5. PMID: 18349101.
      Citations:    
    65. Rosman DS, Phukan S, Huang CC, Pasche B. TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Res. 2008 Mar 01; 68(5):1319-28. PMID: 18316594.
      Citations:    
    66. Pasche B. Recent advances in breast cancer genetics. Cancer Treat Res. 2008; 141:1-10. PMID: 18274079.
      Citations:    
    67. Pennison M, Pasche B. Targeting transforming growth factor-beta signaling. Curr Opin Oncol. 2007 Nov; 19(6):579-85. PMID: 17906455.
      Citations:    
    68. Bian Y, Knobloch TJ, Sadim M, Kaklamani V, Raji A, Yang GY, Weghorst CM, Pasche B. Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development. Hum Mol Genet. 2007 Dec 15; 16(24):3128-35. PMID: 17890272.
      Citations:    
    69. DeAngelis CD, Fontanarosa PB, King MC, Pasche B. Genetics and genomics: a call for papers. Arch Surg. 2007 Sep; 142(9):822. PMID: 17875835.
      Citations:    
    70. Xu Y, Pasche B. TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet. 2007 Apr 15; 16 Spec No 1:R14-20. PMID: 17613544.
      Citations:    
    71. Rosman DS, Kaklamani V, Pasche B. New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol. 2007 Feb; 8(1):61-73. PMID: 17634833.
      Citations:    
    72. Pasche B. A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage. JAMA. 2006 Jun 07; 295(21):2537-8. PMID: 16757727.
      Citations:    
    73. Levin B, Barthel JS, Burt RW, David DS, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton S, Kohlmann W, Ludwig KA, Lynch PM, Marino C, Martin EW, Mayer RJ, Pasche B, Pirruccello SJ, Rajput A, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, Winawer SJ. Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):384-420. PMID: 16569391.
      Citations:    
    74. Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2006 Feb; 4(2):156-76. PMID: 16451772.
      Citations:    
    75. Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, Kaklamani V, Baddi L, Siddiqui FS, Frankel W, Prior TW, Schuller DE, Agrawal A, Lang J, Dolan ME, Vokes EE, Lane WS, Huang CC, Caldes T, Di Cristofano A, Hampel H, Nilsson I, von Heijne G, Fodde R, Murty VV, de la Chapelle A, Weghorst CM. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA. 2005 Oct 05; 294(13):1634-46. PMID: 16204663.
      Citations:    
    76. Bian Y, Caldes T, Wijnen J, Franken P, Vasen H, Kaklamani V, Nafa K, Peterlongo P, Ellis N, Baron JA, Burn J, Moeslein G, Morrison PJ, Chen Y, Ahsan H, Watson P, Lynch HT, de la Chapelle A, Fodde R, Pasche B. TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol. 2005 May 01; 23(13):3074-8. PMID: 15860866.
      Citations:    
    77. Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, Offit K, Pasche B. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res. 2005 Apr 15; 65(8):3454-61. PMID: 15833881.
      Citations:    
    78. Kaklamani V, Pasche B. Transforming Growth Factor Beta and breast cancer. Cancer Treat Res. 2005; 126:129-56. PMID: 16209065.
      Citations:    
    79. Kaklamani V, Baddi L, Rosman D, Liu J, Ellis N, Oddoux C, Ostrer H, Chen Y, Ahsan H, Offit K, Pasche B. No major association between TGFBR1*6A and prostate cancer. BMC Genet. 2004 Sep 22; 5:28. PMID: 15385056.
      Citations:    
    80. Kaklamani VG, Pasche B. Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther. 2004 Aug; 4(4):649-61. PMID: 15270668.
      Citations:    
    81. Patel JD, Pasche B, Argiris A. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Crit Rev Oncol Hematol. 2004 Jun; 50(3):175-86. PMID: 15182824.
      Citations:    
    82. Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss M, Zheng T. TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol. 2004 Feb 15; 22(4):756-8. PMID: 14966109.
      Citations:    
    83. Pasche B, Serhan CN. Is C-reactive protein an inflammation opsonin that signals colon cancer risk? JAMA. 2004 Feb 04; 291(5):623-4. PMID: 14762043.
      Citations:    
    84. Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol. 2003 Sep 01; 21(17):3236-43. PMID: 12947057.
      Citations:    
    85. Bian Y, Kaklamani V, Reich J, Pasche B. TGF-beta signaling alterations in cancer. Cancer Treat Res. 2003; 115:73-94. PMID: 12613193.
      Citations:    
    86. Pasche B, Mulcahy M, Benson AB. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best Pract Res Clin Gastroenterol. 2002 Apr; 16(2):331-45. PMID: 11969242.
      Citations:    
    Pasche's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (324)
    Explore
    _
    Co-Authors (57)
    Explore
    _
    Similar People (58)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _